Results 171 to 180 of about 5,827,952 (364)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

open access: yesMolecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen   +9 more
wiley   +1 more source

Item 1, Drawing #10027A, "I-59", Diagrams for Lavatory, Closet, and Sink Backing, 1910 [PDF]

open access: yes, 1910
The Double U Company was a land colonization business chartered in 1907 by breakfast food magnate Charles William Post (1854-1914) of Battle Creek, Michigan.

core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Item 86, Drawing #13012, "D-24", Sheet 2, Floor plan of unidentified house, incomplete, 1913 [PDF]

open access: yes, 1913
The Double U Company was a land colonization business chartered in 1907 by breakfast food magnate Charles William Post (1854-1914) of Battle Creek, Michigan.

core  

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen   +14 more
wiley   +1 more source

Item 78, Drawing #09026, "Q-0009", Plat of Lot Containing House on Acre Plat No. 19, 1909 [PDF]

open access: yes, 1909
The Double U Company was a land colonization business chartered in 1907 by breakfast food magnate Charles William Post (1854-1914) of Battle Creek, Michigan.

core   +1 more source

L’artiste de bande dessinée et son miroir : l’autoportrait détourné

open access: yesComicalités, 2013
Writing about itself does not necessarily come with a strong concern for the representation of itself: self-portrait remains, in general, relatively dispassionate or disembodied. One may wonder if comics, traditionally an art of the character, is open to
Catherine Mao
doaj  

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Item 28, Drawing #10012A, Sheet 1-2 (2 sheets), "F-22", Plan, elevation, and section views of unidentified commercial structure, 1910 [PDF]

open access: yes, 1910
The Double U Company was a land colonization business chartered in 1907 by breakfast food magnate Charles William Post (1854-1914) of Battle Creek, Michigan.

core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy